(Q52873401)

9 May 2018

title

Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. (English)

1 reference

9 May 2018

1 reference

2

1 reference

9 May 2018

Robert Zeillinger

8

1 reference

9 May 2018

Diether Lambrechts

13

object named as

Diether Lambrechts

1 reference

9 May 2018

14

Ignace Vergote

1 reference

9 May 2018

Frédéric Amant

11

object named as

Frédéric Amant

1 reference

9 May 2018

author name string

Evelyn Despierre

1

1 reference

9 May 2018

Betül Yesilyurt

3

1 reference

9 May 2018

Jalid Sehouli

4

1 reference

9 May 2018

Ioana Braicu

5

1 reference

9 May 2018

Sven Mahner

6

1 reference

9 May 2018

Dan Cacsire Castillo-Tong

7

1 reference

9 May 2018

Sandrina Lambrechts

9

1 reference

9 May 2018

Karin Leunen

10

1 reference

9 May 2018

Philippe Moerman

12

1 reference

9 May 2018

language of work or name

English

0 references

publication date

2 October 2014

1 reference

9 May 2018

published in

Gynecologic Oncology

1 reference

9 May 2018

volume

135

1 reference

9 May 2018

issue

3

1 reference

9 May 2018

page(s)

415-422

1 reference

9 May 2018

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

The resurgence of platinum-based cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Ovarian cancer: strategies for overcoming resistance to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Clinical trials in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Allele-specific copy number analysis of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.09.014

10.1016/J.YGYNO.2014.09.014

7 January 2021

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018